English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17423/19718 (88%)
Visitors : 6233581      Online Users : 779
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/32575


    標題: Higher nuclear EGFR expression is a better predictor of survival in rectal cancer patients following neoadjuvant chemoradiotherapy than cytoplasmic EGFR expression
    作者: Yang, Ching-Chieh
    Lin, Li-Ching
    Lin, Yu-Wei
    Yu-Feng Tian(田宇峯)
    Lin, Chen-Yi
    Sheu, Ming-Jen
    Li, Chien-Feng
    Tai, Ming-Hong
    貢獻者: Chi Mei Med Ctr, Dept Radiat Oncol
    Natl Sun Yat Sen Univ, Inst Biomed Sci
    Chia Nan Univ Pharm & Sci, Dept Pharm
    Chi Mei Med Ctr, Div Gen Surg, Dept Surg
    Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
    Chi Mei Med Ctr, Dept Internal Med, Div Gastroenterol & Hepatol
    Chi Mei Med Ctr, Dept Pathol
    Natl Hlth Res Inst, Natl Inst Canc Res
    Southern Taiwan Univ Sci & Technol, Dept Biotechnol
    Natl Sun Yat Sen Univ, Ctr Neurosci
    關鍵字: epidermal growth factor receptor
    nuclear
    rectal cancer
    chemoradiotherapy
    survival analysis
    日期: 2019-02
    上傳時間: 2020-07-29 13:50:30 (UTC+8)
    出版者: SPANDIDOS PUBL LTD
    摘要: The aim of the present study was to investigate the prognostic value of cytoplasmic (-C) and nuclear epidermal growth factor receptor (EGFR-N) expression in rectal cancer patients following neoadjuvant concurrent chemoradiotherapy (CCRT). A total of 172 newly diagnosed rectal cancer patients post-neoadjuvant CCRT and curative surgery, treated between January 1998 to December 2008, were included. Pathological tissues used for evaluation were biopsy specimens obtained prior to CCRT, and specimens collected at surgery. EGFR expression in the nucleus and cytoplasm was assessed by immunohistochemistry tests. An intensity of 3+ EGFR reactivity in the cytoplasm (and/or membrane) of tumor cells was defined as overexpression of EGFR-C. The cutoff percentage of immunoreactive tumor cells for EGFR-N overexpression was 50%. Expression levels of EGFR-C and EGFR-N were further analyzed by clinicopathological features for 5-year survival disease-specific survival (DSS), local recurrence-free survival (LRFS) and metastasis-free survival (MeFS). The results revealed that 20.9 and 23.3% of the cohort had high EGFR-N and EGFR-C expression, respectively. EGFR-N overexpression was significantly associated with advanced pre-treatment tumor stage (T3 and 4; P=0.017) and post-treatment tumor stage (T3 and 4; P<0.001). In univariate analysis, EGFR-N overexpression was significantly associated with poorer DSS (P=0.0005), MeFS (P=0.0182), and LRFS (P=0.0014). Furthermore, it remained an independent prognosticator of worse DSS [P=0.007, hazard ratio (HR)=2.755] and LRFS (P=0.0164, HR=3.026) in multivariate analysis. Overexpression of EGFR-N, and not EGFR-C, may help identify rectal cancer patients who have an increased risk of local recurrence and poor survival following neoadjuvant CCRT.
    關聯: Oncology Letters, v.17, n.2, pp.1551-1558
    Appears in Collections:[保健營養系(所) ] 期刊論文

    Files in This Item:

    File Description SizeFormat
    10.3892-ol.2018.9756.pdf1112KbAdobe PDF14View/Open
    index.html0KbHTML17View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback